Patents by Inventor Jennifer Riggs-Sauthier

Jennifer Riggs-Sauthier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190175743
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: February 15, 2019
    Publication date: June 13, 2019
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Patent number: 10307416
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 4, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Patent number: 10265411
    Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 23, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Patent number: 10251959
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 9, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Publication number: 20190071454
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • Publication number: 20190046523
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 14, 2019
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Publication number: 20190029991
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 31, 2019
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • Publication number: 20190030182
    Abstract: Compounds comprising a binding moiety, water-soluble, non-peptidic polymer, and drug are provided. Also provided are methods preparing such compounds, compositions comprising such compounds and methods for administering and using such compounds and compositions.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 31, 2019
    Inventors: Jennifer Riggs-Sauthier, Deborah H. Charych, Clark Norman Eid, JR., Dennis G. Fry, Marina Konakova, Christine Frances Loehrlein
  • Patent number: 10189859
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 29, 2019
    Assignee: Nektar Therapeutics
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • Publication number: 20190002399
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Application
    Filed: August 28, 2018
    Publication date: January 3, 2019
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Patent number: 10143690
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: December 4, 2018
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Publication number: 20180256599
    Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
    Type: Application
    Filed: October 19, 2017
    Publication date: September 13, 2018
    Inventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
  • Publication number: 20180256563
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: October 24, 2017
    Publication date: September 13, 2018
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Publication number: 20180243429
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Patent number: 10039737
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: August 7, 2018
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • Publication number: 20180185499
    Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 5, 2018
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier, Neel K. Anand
  • Publication number: 20180185496
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 5, 2018
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Publication number: 20180140712
    Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Application
    Filed: January 19, 2018
    Publication date: May 24, 2018
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Patent number: 9943605
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: April 17, 2018
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Patent number: 9937266
    Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 10, 2018
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier, Neel K. Anand